目前正在进行的一项治疗多形性胶质母细胞瘤(GBM)的潜在关键研究正在进行中,预计年底前中期分析的TOPLINE数据将对该研究进行评估 德克萨斯州休斯顿/ACCESSWIRE/2023年8月14日/CNS制药公司(纳斯达克股票代码:CNSP)今天在2023年8月10日至12日于加利福尼亚州旧金山举行的2023年8月10日至12日在加利福尼亚州旧金山举行的20...
HOUSTON, TX / ACCESSWIRE / August 3, 2023 /CNS PHARMACEUTICALSInc. (NASDAQ:CNSP)(“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary metastatic cancers in the ...
November 18, 2023. Accessed November 21, 2023. https://tinyurl.com/aan35bx4 2. Glioblastoma treatment with irradiation and olaptesed pegol (NOX-A12) in MGMT unmethylated patients (GLORIA). ClinicalTrials.gov. Updated June 22, 2023. Accessed November 21, 2023. https://clinicaltrials.gov/...
[2]Immunotherapy turned brain cancers from ‘cold’ to ‘hot’ in mouse study, as clinical trials advance,Retrieved May 25, 2023, from网页链接 @药明康德内容团队编辑 本文来自药明康德内容团队,欢迎转发,谢绝转载到其他平台。 免责声明:药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目...
As the world's first global "adaptive" clinical trial for brain cancer, GBM AGILE allows glioblastoma patients to quickly share in the benefits of more effective therapies at a faster, more effective pace. Providing new hope where little currently exists. These trials can help up to 50 GBM ...
Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl ...
A number of challenges are evident in the design of immunotherapy clinical trials in glioblastoma including patient selection, immune and imaging response monitoring, and evaluation of clinical outcome. 展开 关键词: Glioblastoma Immunotherapy Vaccines Immune checkpoint inhibitors Virotherapy ...
INB-400 于 2023年 4月被 FDA授予孤儿药资格,用于治疗多形性胶质母细胞瘤 (GBM),这是首个获得这一监管资格的转基因 γ-δ T 细胞疗法。GBM 仍然是一个重要的未满足的需求,GBM 是高度侵袭性和难以治疗的脑癌,治疗方案和相关结果在超过 18年的时间里基本保持不变,中位无进展生存期为 6-7个月,总生存期...
Checkpoint kinase1 (CHK1) is a DNA damage kinase, which has been observed to be constitutively active in human cancers. Unfortunately a number of new generation CHK1 inhibitors, currently in clinical trials, have shown deleterious effects on normal cells, thus limiting their clinical utility. Ther...
Immunotherapy in cervical cancer: from the view of scientometric analysis and clinical trials Front Immunol, 14 (2023), Article 1094437 View in ScopusGoogle Scholar 16 W. Zhou, X. Wang Human gene therapy: a scientometric analysis Biomed Pharmacother, 138 (2021), Article 111510 View in ScopusGoog...